Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide

Background: Acute promyelocytic leukemia (APL) is a model for synergistic target cancer therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which yields a very high 5-year overall survival (OS) rate of 85 to 90%. Nevertheless, about 15% of APL patients still get early death or r...

Full description

Bibliographic Details
Main Authors: Yang Shen, Ya-Kai Fu, Yong-Mei Zhu, Yin-Jun Lou, Zhao-Hui Gu, Jing-Yi Shi, Bing Chen, Chao Chen, Hong-Hu Zhu, Jiong Hu, Wei-Li Zhao, Jian-Qing Mi, Li Chen, Hong-Ming Zhu, Zhi-Xiang Shen, Jie Jin, Zhen-Yi Wang, Jun-Min Li, Zhu Chen, Sai-Juan Chen
Format: Article
Language:English
Published: Elsevier 2015-06-01
Series:EBioMedicine
Subjects:
Acute promyelocytic leukemia
Epigenetic
Prognosis
Mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396415001000

Internet

http://www.sciencedirect.com/science/article/pii/S2352396415001000

Similar Items